Nebido Will Emerge As Hypogonadism Treatment Leader, Indevus Says
This article was originally published in The Pink Sheet Daily
Indevus expects Nebido to acquire the majority of the injectable testosterone hypogonadism treatment market when it launches in the U.S., the company said in an Aug. 9 earnings call
You may also be interested in...
Indevus expects to file an NDA for the injectable testosterone therapy, licensed from Schering AG, for the treatment of hypogonadism in the second half of 2006.
Esprit’s 100 sales reps will initially target marketing efforts to 8,000 urologist offices, with eventual movement to ob/gyn and family practitioners.
The firm will restate first quarter and 2004 year-end results due to less-than-expected returns of the anabolic agent.